nach oben

Diabetologia

Erschienen in:

01.09.2006 | Article

Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer’s disease and decreases it in wild-type mice

verfasst von: E. Galea, D. L. Feinstein, P. Lacombe

Erschienen in: Diabetologia | Ausgabe 9/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Clinical trials are in progress to test thiazolidinediones in neurodegenerative diseases such as Alzheimer’s disease that involve deficiencies in brain glucose metabolism. While thiazolidinediones enhance glucose uptake in non-cerebral tissues, their impact on brain energy metabolism has not been investigated in vivo. We thus determined whether the thiazolidinedione pioglitazone reverses the decrease in cerebral glucose utilisation (CGU) in a model of brain metabolic deficiency related to Alzheimer’s disease. Results are relevant to diabetes because millions of diabetic patients take pioglitazone as an insulin-sensitising drug, and diabetes increases the risk of developing Alzheimer’s disease.

Materials and methods

The regional pattern of CGU was measured with the 2-deoxy [¹⁴C] glucose autoradiographic technique in adult awake mice overexpressing transforming growth factor β1 (TGFβ1), and in wild-type littermates. Mice were treated with pioglitazone for 2 months.

Results

Measurement of CGU in 27 brain regions confirmed that TGFβ1 overexpression induced hypometabolism across the brain. Pioglitazone did not reverse the effect of TGFβ1 overexpression and decreased regional CGU in control animals by up to 23%. The extent of the regional CGU decrease induced by pioglitazone, but not that induced by TGFβ1, correlated strongly with basal CGU, suggesting that the higher the local metabolic rate the greater the reduction of CGU effected by pioglitazone.

Conclusions/interpretation

In contrast to its stimulatory effect in non-cerebral tissues, chronic treatment with pioglitazone decreases CGU in vivo. This evidence does not support the hypothesis that pioglitazone could act as a metabolic enhancer in Alzheimer’s disease, and raises the question of how thiazolidinediones could be beneficial in neurodegenerative diseases.

Hammarstedt A, Sopasakis VR, Gogg S, Jansson PA, Smith U (2005) Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia 48:96–104PubMedCrossRef

Kubota N, Terauchi Y, Kubota T et al (2006) Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin dependent and independent pathway. J Biol Chem 281:8748–8755PubMedCrossRef

Heneka MT, Klockgether T, Feinstein DL (2000) Peroxisome proliferator-activated receptor-γ ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20:6862–6867PubMed

Cunard R, Eto Y, Muljadi JT, Glass CK, Kelly CJ, Ricote M (2004) Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. J Immunol 172:7530–7536PubMed

Schutz B, Reimann J, Dumitrescu-Ozimek L et al (2005) The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 25:7805–7812PubMedCrossRef

Feinstein DL (2004) Contrasting the neuroprotective and gliotoxic effects of PPARγ agonists. Drug Discov Today Ther Strategy 1:29–34CrossRef

Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proliferator activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. Neurochemistry 82:615–624CrossRef

Lacombe P, Mathews PM, Schmidt SD et al (2004) Effect of anti-inflammatory agents on transforming growth factor beta overexpressing mouse brains: a model revised. J Neuroinflammation 1:1–17CrossRef

Dello-Russo C, Gavrilyuk V, Weinberg G et al (2003) Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 278:5828–5836PubMedCrossRef

10.

Brunmair B, Staniek K, Gras F et al (2004) Thiazolidinediones, like metformin, inhibit respiratory complex I. A common mechanism contributing to their anti-diabetic actions? Diabetes 53:1052–1059PubMedCrossRef

11.

Feinstein DL, Spagnolo A, Akar C et al (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem Pharmacol 70:177–188PubMedCrossRef

12.

Konrad D, Rudich A, Bilan PJ et al (2005) Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. Diabetologia 48:954–966PubMedCrossRef

13.

Petersen KF, Dufour S, Shulman GI (2005) Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med 2:e233PubMedCrossRef

14.

Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57:695–703PubMedCrossRef

15.

Sokoloff L (1981) Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose. J Cereb Blood Flow Metab 1:7–36PubMed

16.

El-Kebbi IM, Roser S, Pollet RJ (2004) Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism 43:953–958CrossRef

17.

Shimaya A, Kurosaki E, Shioduka K, Nakano R, Shibasaki M, Shika H (1998) YM268 increases the glucose uptake, cell differentiation and mRNA expression of glucose transporter 3T3-L1 adipocytes. Horm Metab Res 30:543–548PubMedCrossRef

18.

Sorbi S, Bird ED, Blass JP (1983) Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol 13:72–78PubMedCrossRef

19.

de Leon MJ, Convit A, Wolf OT et al (2001) Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxyglucose/positron-emission tomography (FDC/PET). Proc Natl Acad Sci USA 98:10966–10971PubMedCrossRef

20.

Craft S, Zallen G, Baker LD (1992) Glucose and memory in mild senile dementia of the Alzheimer type. J Clin Exp Neuropsychol 14:253–267PubMedCrossRef

21.

Craft S, Asthana S, Cook DG et al (2003) Insulin dose-response effects on memory and plasmid amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28:809–822PubMedCrossRef

22.

Watson GS, Craft S (2004) Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer’s disease. Eur J Pharmacol 490:97–113PubMedCrossRef

23.

Gibson GE, Sheu KF, Blass JP (1998) Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Trans 105:855–870CrossRef

24.

Convit A, Wolf OT, Tarshish C, de Leon MJ (2003) Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly. Proc Natl Acad Sci USA 100:2019–2022PubMedCrossRef

25.

Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer’s disease. Eur J Pharmacol 490:115–125PubMedCrossRef

26.

Watson GS, Cholerton BA, Reger MA et al (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13:950–958PubMedCrossRef

27.

Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer’s disease and decline in cognitive function. Arch Neurol 61:661–666PubMedCrossRef

28.

Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes – systematic overview of prospective observational studies. Diabetologia 48:2460–2469PubMedCrossRef

29.

Wyss-Coray T, Lin C, Sanan DA, Mucke L, Masliah E (2000) Chronic overproduction of transforming growth factor-β1 by astrocytes promotes Alzheimer’s disease-like microvascular degeneration in transgenic mice. Am J Pathol 156:139–150PubMed

30.

Wyss-Coray T, Lin C, Von Euw D, Masliah E, Mucke L, Lacombe P (2000) Alzheimer’s disease-like cerebrovascular pathology in TGFβ1 transgenic mice and functional metabolic correlates. Ann NY Acad Sci 903:317–323PubMedCrossRef

31.

Gaertner RF, Wyss-Coray T, Von Euw D, Lesné S, Vivien D, Lacombe P (2005) Reduced brain tissue perfusion in TGFβ1 transgenic mice showing Alzheimer’s disease-like cerebrovascular abnormalities. Neurobiol Dis 19:38–46PubMedCrossRef

32.

Tong XK, Nicolakakis N, Kocharyan A, Hamel E (2005) Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer’s disease. J Neurosci 25:11165–1174PubMedCrossRef

33.

Lautermäki R, Airaksinen KE, Seppanen M et al (2005) Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes 54:2787–2794CrossRef

34.

Magistretti PJ, Pellerin L (1996) Cellular bases of brain energy metabolism and their relevance to functional brain imaging: evidence for a prominent role of astrocytes. Cerebral Cortex 6:50–61PubMedCrossRef

35.

Carro E, Torres-Aleman I (2004) The role of insulin and insulin-like growth factor-I in the molecular and cellular mechanisms underlying the pathology of Alzheimer’s disease. Eur J Pharmacol 490:127–133PubMedCrossRef

36.

Steen E, Terry BM, Rivera EJ et al (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease – is this type 3 diabetes? J Alzheimers Dis 7:63–80

37.

Smith D, Pernet A, Hallett WA, Bingham E, Marsden PK, Amiel SA (2003) Lactate: a preferred fuel for human brain metabolism in vivo. J Cereb Blood Flow Metab 23:658–664PubMedCrossRef

38.

Collino M, Aragno M, Mastrocola R et al (2006) Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 530:70–80PubMedCrossRef

39.

Lortz S, Gurgul-Convey E, Lenzen S, Tiedge M (2005) Importance of mitochondrial superoxide dismutase expression in insulin-producing cells for the toxicity of reactive oxygen species and proinflammatory cytokines. Diabetologia 48:1541–1548PubMedCrossRef

40.

Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2003) Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with IkappaB alpha induction and block of NFkappaB and iNOS activation. J Neurochem 88:494–501CrossRef

41.

Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE (2005) Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130:685–696PubMedCrossRef

42.

Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol (Epub ahead of print) DOI 10.1016/j.expneurol.2006.01.018

Titel: Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer’s disease and decreases it in wild-type mice
verfasst von: E. Galea
D. L. Feinstein
P. Lacombe
Publikationsdatum: 01.09.2006
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 9/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0326-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2006

Dysregulation of muscle fatty acid metabolism in type 2 diabetes is independent of malonyl-CoA

Within-patient variation of the pharmacokinetics of subcutaneously injected biphasic insulin aspart as assessed by compartmental modelling

The UK case–control study of cerebral oedema complicating diabetic ketoacidosis in children

Prenatal viral exposure followed by adult stress produces glucose intolerance in a mouse model

Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function